NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Low Pathogenicity Avian H10N7 Influenza Virus in a Healthy Human Challenge Model

Phase 1

Recruiting

Conditions: Influenza Infection

Interventions: Biological: A/Mallard/Ohio-99/MM4/1989 H10N7

First Posted Date: 2022-06-29

Last Posted Date: 2024-11-14

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 200

Registration Number: NCT05436444

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

A Study of the Safety, Tolerability, and Pharmacokinetics of Dolutegravir in Neonates Exposed to HIV-1

Phase 1

Recruiting

Conditions: HIV

Interventions: Drug: Dolutegravir 0.5 mg/kg oral suspension
Drug: Dolutegravir 5 mg Dispersible Tablets

First Posted Date: 2022-06-06

Last Posted Date: 2024-08-21

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 36

Registration Number: NCT05406583

Locations: 🇺🇸
University of Southern California NICHD CRS, Los Angeles, California, United States
🇵🇷
University of Puerto Rico Pediatric HIV/AIDS Research CRS, San Juan, Puerto Rico
🇹🇭
Siriraj Hospital, Mahidol University NICHD CRS, Bangkok, Thailand

and more 15 locations

Dose Escalation, Open-Label Clinical Trial to Evaluate Safety, Tolerability and Immunogenicity of a Nipah Virus (NiV) mRNA Vaccine, mRNA-1215, in Healthy Adults

Phase 1

Active, not recruiting

Conditions: Nipah Virus Infection

Interventions: Biological: mRNA -1215

First Posted Date: 2022-06-01

Last Posted Date: 2024-07-31

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 50

Registration Number: NCT05398796

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Anti-malaria MAb in Kenyan Children

Phase 2

Recruiting

Conditions: Plasmodium Falciparum Infection
Malaria

Interventions: Drug: L9LS
Other: Normal Saline

First Posted Date: 2022-06-01

Last Posted Date: 2024-04-16

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 720

Registration Number: NCT05400655

Locations: 🇰🇪
Kenya Medical Research Institute (KEMRI) Center for Global Health Research (CGHR), Kisumu, Kenya

Evaluate the Efficacy and Safety of Ruxolitinib on Hair Regrowth in Patients With Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy (APECED)-Associated Alopecia Areata

Phase 2

Recruiting

Conditions: Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy (Apeced)
Alopecia Areata

Interventions: Drug: Ruxolitinib

First Posted Date: 2022-06-01

Last Posted Date: 2024-12-30

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 70

Registration Number: NCT05398809

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Trial of a Six-Month Regimen of High-Dose Rifampicin, High-Dose Isoniazid, Linezolid, and Pyrazinamide Versus a Standard Nine-Month Regimen for the Treatment of Adults and Adolescents With Tuberculous Meningitis

Phase 2

Recruiting

Conditions: Tuberculous Meningitis

Interventions: Drug: Rifampicin (RIF)
Drug: ethambutol (EMB)
Drug: Isoniazid (INH)
Drug: Linezolid (LZD)
Drug: Rifampicin
Drug: Pyrazinamide (PZA)
Drug: Isoniazid

First Posted Date: 2022-05-20

Last Posted Date: 2024-08-21

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 330

Registration Number: NCT05383742

Locations: 🇲🇼
Malawi CRS, Lilongwe, Malawi
🇧🇷
Hospital Nossa Senhora da Conceicao CRS (12201), Porto Alegre, Brazil
🇧🇷
Instituto de Pesquisa Clinica Evandro Chagas (IPEC) CRS (12101), Rio De Janeiro, Brazil

and more 13 locations

Prevention of Asthma Exacerbations Using Dupilumab in Urban Children and Adolescents

Phase 2

Recruiting

Conditions: Asthma

Interventions: Drug: Placebo
Drug: Dupilumab

First Posted Date: 2022-04-26

Last Posted Date: 2024-06-28

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 240

Registration Number: NCT05347771

Locations: 🇺🇸
Boston Children's Hospital: Department of Immunology, Boston, Massachusetts, United States
🇺🇸
Cincinnati Children's Hospital Medical Center: Asthma Center, Cincinnati, Ohio, United States
🇺🇸
Children's National Medical Center: Children's Research Institute, Washington, District of Columbia, United States

and more 4 locations

Fecal Microbiota Transplantation for Chronic Granulomatous Disease-Associated Colitis

Phase 1

Recruiting

Conditions: Chronic Granulomatous Disease-associated Colitis

Interventions: Drug: MTP 101-LF

First Posted Date: 2022-04-19

Last Posted Date: 2024-12-19

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 20

Registration Number: NCT05333471

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

CD40L Antagonism in Rheumatoid Arthritis (RA)

Phase 2

Active, not recruiting

Conditions: Rheumatoid Arthritis

Interventions: Drug: Placebo for VIB4920
Drug: VIB4920 with TNFi
Drug: VIB4920 without TNFi

First Posted Date: 2022-04-01

Last Posted Date: 2024-02-01

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 104

Registration Number: NCT05306353

Locations: 🇺🇸
University of California San Francisco School of Medicine: Lupus Clinic and Rheumatology Clinical Research Center, San Francisco, California, United States
🇺🇸
University of Colorado School of Medicine: Division of Rheumatology, Aurora, Colorado, United States
🇺🇸
Brigham & Women's Hospital: Department of Medicine, Rheumatology, Immunology, Boston, Massachusetts, United States

and more 2 locations

Examining Distinct Immunophenotypes to Validate and Enhance Rational Treatment in Systemic Lupus

Phase 2

Recruiting

Conditions: Systemic Lupus Erythematosus

Interventions: Drug: Placebo for Voclosporin
Drug: Placebo for Mycophenolate Mofetil
Drug: Mycophenolate Mofetil
Drug: Voclosporin

First Posted Date: 2022-04-01

Last Posted Date: 2024-01-19

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 120

Registration Number: NCT05306873

Locations: 🇺🇸
UCLA Medical Center: Division of Rheumatology, Los Angeles, California, United States
🇺🇸
Yale University School of Medicine: Rheumatology, Allergy & Immunology, New Haven, Connecticut, United States
🇺🇸
Emory University School of Medicine: Division of Rheumatology, Atlanta, Georgia, United States

and more 8 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy